Global Adalimumab Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
USD
20,912.10 Billion
USD
31,610.01 Billion
2021
2029
 Período de pronóstico |
2022 –2029 |
 Tamaño del mercado (año base) |
USD 20,912.10 Billion |
 Tamaño del mercado (año de pronóstico) |
USD 31,610.01 Billion |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Global Adalimumab Market, By Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the adalimumab market is anticipated to grow rapidly during the forecast period. Adalimumab, which was first licensed in the United States, is now available in more than 60 countries. Its global market is consolidated, with only a few firms attempting to outsmart one other on price. Most of the major players are currently concentrating their efforts on the development of adalimumab biosimilars for the treatment of rheumatoid arthritis and psoriasis. This is seen in clinical trials testing the safety and efficacy of adalimumab biosimilars in the treatment of medical disorders. Many inflammatory disorders in adults are treated with adalimumab, including ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.
Data Bridge Market Research analyses that the adalimumab market was valued at USD 20,912.1 million in 2021 and is expected to reach USD 31,610.01 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Adalimumab is a prescription medicine which is sold under the brand names Humira and Exemptia. heumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis are all treated with adalimumab. TNF (tumour necrosis factor alpha) is commonly bound by adalimumab. When TNF interacts to TBF receptors, an inflammatory response to autoimmune illness is triggered. By binding to a TNF, adalimumab reduces the likelihood of an inflammatory response.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Clase de fármaco (antirreumáticos, inhibidores del TNF alfa, otros), indicación (artritis reumatoide, espondilitis anquilosante, psoriasis en placas crónica, enfermedad de Crohn, colitis ulcerosa, artritis psoriásica, artritis idiopática juvenil, hidradenitis supurativa, intermedio no infeccioso, otros), tipo (biológicos, biosimilares), dosis (40 mg/0,4 mlg, 80 mg/0,8 mlg, 20 mg/0,2 mlg, 10 mg/0,1 mlg, otros), tipo de fármaco (de marca, genéricos), vía de administración (oral, parenteral, otros), grupo de edad (pediátrico, adulto, geriátrico), forma farmacéutica (comprimido, inyección, solución, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, venta minorista) Farmacia, Farmacia Online, Otros) |
|
Países cubiertos |
EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur |
|
Actores del mercado cubiertos |
F. Hoffmann-La Roche Ltd. (Suiza), Mylan NV (EE. UU.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (Francia), Pfizer Inc. (EE. UU.), GlaxoSmithKline plc (Reino Unido), Novartis AG (Suiza), Zydus Cadila (India), Biogen (EE. UU.), Fresenius Kabi AG (Alemania), Boehringer Ingelheim International GmbH. (Alemania), Amgen Inc. (EE. UU.), AbbVie Inc. (EE. UU.), Abbott (EE. UU.), CELLTRION INC. (Corea del Sur), Samsung Bioepis (Corea del Sur), Coherus BioSciences (EE. UU.), Innovent Biologics, Inc. (China), Hetero Biopharma Ltd. (India), Reliance Life Sciences (India) |
|
Oportunidades de mercado |
|
Dinámica del mercado de adalimumab
Conductores
- Aumento de la tasa de incidencia de enfermedades autoinmunes
Se prevé que el aumento de la incidencia de enfermedades autoinmunes como la artritis psoriásica, la psoriasis en placas, la colitis ulcerosa, la espondilitis anquilosante, la artritis reumatoide y la enfermedad de Crohn impulsen la tasa de crecimiento del mercado. Junto con esto, la creciente prevalencia de trastornos crónicos aumentará la demanda del mercado de adalimumab.
- Aumentar la inversión en infraestructura sanitaria
Otro factor importante que influye en la tasa de crecimiento del mercado de adalimumab es el creciente gasto en atención médica que ayuda a mejorar su infraestructura.
- Aumento de la población geriátrica
El aumento de la población geriátrica impulsará la tasa de crecimiento del mercado durante el período de pronóstico de 2022 a 2029. Según la investigación World Ageing 2020, la población mundial será de aproximadamente 727 millones de personas de 65 años o más en 2020. En 2050, se espera que el número de personas mayores aumente a 1.500 millones. La población geriátrica es más propensa a enfermedades crónicas, lo que se prevé que mejore la tasa de crecimiento del mercado.
Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la información y la creciente demanda de medicamentos biosimilares debido a su relación coste-eficacia ampliarán el mercado del adalimumab. Además, los altos ingresos disponibles y el aumento de los casos de infecciones de las vías respiratorias superiores darán lugar a la expansión del mercado del adalimumab.
Oportunidades
- Aumento del número de actividades de investigación y desarrollo
Además, el crecimiento del mercado se ve impulsado por un aumento en el número de actividades de investigación y desarrollo, lo que brindará oportunidades beneficiosas para el crecimiento del mercado de adalimumab. Junto con esto, el aumento de las aprobaciones y lanzamientos de medicamentos impulsará aún más la tasa de crecimiento del mercado.
Además, la creciente inversión para el desarrollo de tecnologías avanzadas y el aumento del número de mercados emergentes brindarán más oportunidades beneficiosas para el crecimiento del mercado de adalimumab durante el período de pronóstico.
Restricciones/Desafíos
Por otro lado, el alto costo asociado con la fabricación y la naturaleza compleja de la molécula obstaculizarán la tasa de crecimiento del mercado. La falta de infraestructura de atención médica en las economías en desarrollo y el estricto proceso regulatorio vinculado con la aprobación de productos biosimilares desafiarán el mercado de adalimumab. Además, los efectos secundarios relacionados con adalimumab, como náuseas, vómitos, mareos, sedación, estreñimiento, nerviosismo y otros, actuarán como freno y obstaculizarán aún más la tasa de crecimiento del mercado durante el período de pronóstico de 2022 a 2029.
Este informe de mercado de adalimumab proporciona detalles de los nuevos desarrollos recientes, regulaciones comerciales, análisis de importación y exportación, análisis de producción, optimización de la cadena de valor, participación de mercado, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, análisis estratégico del crecimiento del mercado, tamaño del mercado, crecimientos del mercado de categorías, nichos de aplicación y dominio, aprobaciones de productos, lanzamientos de productos, expansiones geográficas, innovaciones tecnológicas en el mercado. Para obtener más información sobre el mercado de adalimumab, comuníquese con Data Bridge Market Research para obtener un informe de analista, nuestro equipo lo ayudará a tomar una decisión de mercado informada para lograr el crecimiento del mercado.
Análisis de la epidemiología de los pacientes
El mercado de adalimumab también le proporciona un análisis detallado del mercado para el análisis de pacientes, el pronóstico y las curas. La prevalencia, la incidencia, la mortalidad y las tasas de adherencia son algunas de las variables de datos que están disponibles en el informe. Se analizan los análisis de impacto directo o indirecto de la epidemiología en el crecimiento del mercado para crear un modelo estadístico multivariado de cohorte más sólido para pronosticar el mercado en el período de crecimiento.
Impacto de la COVID-19 en el mercado de adalimumab
Desde su aparición en diciembre de 2019, el virus COVID-19 se ha propagado a casi todos los países del planeta, lo que llevó a la Organización Mundial de la Salud (OMS) a declararlo una emergencia de salud pública. El COVID-19, un nuevo coronavirus, fue identificado como el agente causal de los casos de neumonía. Este virus se propagó rápidamente por todo el mundo y mató a un gran número de personas. La Organización Mundial de la Salud (OMS) etiquetó al COVID-19 como una pandemia mundial en marzo de 2020 y recomendó medidas rigurosas para prevenir la propagación de la enfermedad. Desde entonces, la pandemia ha retrasado la expansión del sector sanitario y ha interrumpido la cadena de suministro. Además, los gobiernos de varios países han impuesto confinamientos a nivel nacional para detener la propagación del COVID-19. Del mismo modo, las organizaciones sanitarias de numerosos países de todo el mundo tenían dificultades para continuar con sus actividades de la cadena de suministro. El mercado de adalimumab se vio obstaculizado por la lentitud de la cadena de suministro.
Desarrollo reciente
- En octubre de 2021, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) anunció la aprobación del primer producto biosimilar intercambiable para el tratamiento de diversas enfermedades inflamatorias. La vía de aprobación de biosimilares e intercambiables se estableció para ayudar a los pacientes con afecciones médicas críticas a tener acceso a más opciones de tratamiento. Cyltezo es el primer anticuerpo monoclonal intercambiable y el segundo medicamento biosimilar intercambiable autorizado por la FDA.
Alcance del mercado mundial de adalimumab
El mercado de adalimumab está segmentado en función de la clase de fármaco, el tipo, la indicación, la forma farmacéutica, la concentración de la dosis, el tipo de fármaco, la vía de administración, el grupo de edad, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los escasos segmentos de crecimiento de las industrias y proporcionará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Clase de droga
- Antirreumáticos
- Inhibidores del TNF alfa
- Otros
Indicación
- Artritis reumatoide
- Espondiloartritis anquilosante
- Psoriasis crónica en placas
- Enfermedad de Crohn
- Colitis ulcerosa
- Artritis psoriásica
- Artritis reumatoide juvenil idiopática
- Hidradenitis supurativa
- Intermedio no infeccioso
- Otros
Tipo
- Biológicos
- Biosimilares
Dosis de fuerza
- 40 mg/0,4 ml/g
- 80 mg/0,8 ml/g
- 20 mg/0,2 ml/g
- 10 mg/0,1 ml/g
- Otros
Tipo de droga
- De marca
- Genéricos
Vía de administración
- Oral
- Parenteral
- Otros
Forma de dosificación
- Inyección
- Solución
- Tableta
- Otros
Grupo de edad
- Pediátrico
- Adulto
- Geriátrico
Usuarios finales
- Hospitales
- Clínicas de especialidades
- Cuidado domiciliario
- Otros
Canal de distribución
- Farmacia hospitalaria
- Farmacia minorista
- Farmacia en línea
- Otros
Adalimumab Market Regional Analysis/Insights
The adalimumab market is analysed and market size insights and trends are provided by country, drug class, type, indication, dosage form, dosage strength, drug type, route of administration, age group, end-users and distribution channel as referenced above.
The countries covered in the adalimumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the adalimumab market because of the growing geriatric population and surging prevalence of rheumatoid arthritis in this region. Additionally the rising healthcare expenditure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to surging focus for the development of generic and biosimilar products and increasing number of geriatric population in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Adalimumab Market Share Analysis
The Adalimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adalimumab market.
Some of the major players operating in the adalimumab market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Biogen (US)
- Fresenius Kabi AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Amgen Inc. (US)
- AbbVie Inc. (US)
- Abbott (US)
- CELLTRION INC. (South Korea)
- Samsung Bioepis (South Korea)
- Coherus BioSciences (US)
- Innovent Biologics, Inc. (China)
- Hetero Biopharma Ltd. (India)
- Reliance Life Sciences (India)
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ADALIMUMAB MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 INDICATION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PIPELINE ANALYSIS
4 REGULATORY FRAMEWORK OF GLOBAL ADALIMUMAB MARKET
5 EPIDEMIOLOGY
6 ADALIMUMAB PRESCRIPTION
7 GLOBAL ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO
7.1 REIMBURSEMENT SCENARIO IN THE U.S.
7.2 REIMBURSEMENT SCENARIO IN CHINA
7.3 REIMBURSEMENT SCENARIO IN JAPAN
7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE
7.5 REIMBURSEMENT SCENARIO IN DENMARK
7.6 REIMBURSEMENT SCENARIO IN IRELAND
8 IMPACT OF BIOSIMILAR
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS
9.1.2 INCREASING GERIATRIC POPULATION
9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS
9.1.4 INTRODUCTION TO BIOSIMILARS
9.1.5 EXPLORATION OF EMERGING MARKETS
9.2 RESTRAINTS
9.2.1 HIGH COSTS OF DRUGS
9.2.2 SIDE EFFECTS OF DRUGS
9.2.3 CANCER CAUSING DRUGS
9.3 OPPORTUNITIES
9.3.1 PRESENCE OF PRODUCT PIPELINE
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 INCREASING HEALTHCARE EXPENDITURE
9.3.4 PRESENCE OF REIMBURSEMENT POLICIES
9.4 CHALLENGES
9.4.1 LOSS OF PATENTS
9.4.2 AVAILABILITY OF ALTERNATIVES
9.4.3 LONG APPROVAL PROCEDURE
10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY
10.1 OVERVIEW
10.2 ADALIMUMAB AND COVID-19
10.3 PRICE IMPACT OF COVID-19
10.4 IMPACT ON DEMAND
10.5 IMPACT ON SUPPLY CHAIN
10.6 STRATEGIC DECISIONS FOR MANUFACTURERS
10.7 CONCLUSION
11 GLOBAL ADALIMUMAB MARKET, BY INDICATION
11.1 OVERVIEW
11.2 RHEUMATOID ARTHRITIS
11.3 ANKYLOSING SPONDYLITIS
11.4 CHRONIC PLAQUE PSORIASIS
11.5 CROHN’S DISEASE
11.6 ULCERATIVE COLITIS
11.7 PSORIATIC ARTHRITIS
11.8 JUVENILE IDIOPATHIC ARTHRITIS
11.9 HIDRADENITIS SUPPURATIVA
11.1 NON-INFECTIOUS INTERMEDIATE
11.11 OTHERS
12 GLOBAL ADALIMUMAB MARKET, BY TYPE
12.1 OVERVIEW
12.2 BIOLOGICS
12.3 BIOSIMILARS
12.3.1 ADALIMUMAB-ATTO
12.3.2 ADALIMUMAB-BWWD
12.3.3 ADALIMUMAB-ADBM
12.3.4 ADALIMUMAB-ADAZ
12.3.5 ADALIMUMAB-FKJP
12.3.6 ADALIMUMAB-AFZB
12.3.7 OTHERS
13 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGTH
13.1 OVERVIEW
13.2 40MG/0.4ML
13.3 80MG/0.8ML
13.4 20MG/0.4ML
13.5 10MG/0.1ML
13.6 OTHERS
14 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 BRANDED
14.3 GENERICS
14.3.1 AMJEVITA
14.3.2 HYRIMOZ
14.3.3 HULIO
14.3.4 OTHERS
15 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 PARENTERAL
15.3 ORAL
16 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE
16.1 OVERVIEW
16.2 ADULTS
16.3 CHILDREN
17 GLOBAL ADALIMUMAB MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACIES
18.3 RETAIL PHARMACIES
18.4 ONLINE PHARMACIES
18.5 DIRECT TENDER
18.6 OTHERS
19 GLOBAL ADALIMUMAB MARKET, BY GEOGRAPHY
19.1 OVERVIEW
19.2 NORTH AMERICA
19.2.1 U.S.
19.2.2 CANADA
19.2.3 MEXICO
19.3 EUROPE
19.3.1 GERMANY
19.3.2 U.K
19.3.3 ITALY
19.3.4 FRANCE
19.3.5 SPAIN
19.3.6 NETHERLANDS
19.3.7 RUSSIA
19.3.8 SWITZERLAND
19.3.9 BELGIUM
19.3.10 TURKEY
19.3.11 AUSTRIA
19.3.12 NORWAY
19.3.13 HUNGARY
19.3.14 LITHUANIA
19.3.15 IRELAND
19.3.16 POLAND
19.3.17 REST OF EUROPE
19.4 ASIA- PACIFIC
19.4.1 JAPAN
19.4.2 CHINA
19.4.3 SOUTH KOREA
19.4.4 AUSTRALIA
19.4.5 INDIA
19.4.6 SINGAPORE
19.4.7 MALAYSIA
19.4.8 THAILAND
19.4.9 INDONESIA
19.4.10 PHILIPPINES
19.4.11 VIETNAM
19.4.12 REST OF ASIA-PACIFIC
19.5 SOUTH AMERICA
19.5.1 BRAZIL
19.5.2 ARGENTINA
19.5.3 PERU
19.5.4 REST OF SOUTH AMERICA
19.6 MIDDLE EAST & AFRICA
19.6.1 SAUDI ARABIA
19.6.2 SOUTH AFRICA
19.6.3 UAE
19.6.4 ISRAEL
19.6.5 KUWAIT
19.6.6 EGYPT
19.6.7 REST OF MIDDLE EAST & AFRICA
20 GLOBAL ADALIMUMAB MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21 SWOT
22 COMPANY PROFILES
22.1 ABBVIE INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 BIOGEN
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 PRODUCT PORTFOLIO
22.3.4 RECENT DEVELOPMENTS
22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)}
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 PRODUCT PORTFOLIO
22.4.4 RECENT DEVELOPMENTS
22.5 MYLAN N.V.
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 CELLTRION INC.
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 COHERUS BIOSCIENCES
22.8.1 COMPANY SNAPSHOT
22.8.2 PRODUCT PORTFOLIO
22.8.3 RECENT DEVELOPMENTS
22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)
22.9.1 COMPANY SNAPSHOT
22.9.2 REVENUE ANALYSIS
22.9.3 PRODUCT PORTFOLIO
22.9.4 RECENT DEVELOPMENTS
22.1 HETERO BIOPHARMA LTD.
22.10.1 COMPANY SNAPSHOT
22.10.2 PRODUCT PORTFOLIO
22.10.3 RECENT DEVELOPMENTS
22.11 INNOVENT BIOLOGICS, INC.
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 PFIZER INC.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 ZYDUS CADILA
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENT
23 QUESTIONNAIRE
24 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 GLOBAL ADALIMUMAB MARKET, PIPELINE ANALYSIS
TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.
TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)
TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS
TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT
TABLE 6 GLOBAL ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)
TABLE 7 GLOBAL RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 8 GLOBAL ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 GLOBAL CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 10 GLOBAL CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 11 GLOBAL ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 GLOBAL PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 13 GLOBAL JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 14 GLOBAL HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 15 GLOBAL NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 17 GLOBAL ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 18 GLOBAL BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 19 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 20 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 21 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)
TABLE 22 GLOBAL 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 GLOBAL 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 24 GLOBAL 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 25 GLOBAL 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 26 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 27 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 28 GLOBAL BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 GLOBAL GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 GLOBAL GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 31 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)
TABLE 32 GLOBAL PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)
TABLE 34 GLOBAL ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 GLOBAL CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 GLOBAL ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)
TABLE 37 GLOBAL HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 GLOBAL SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 GLOBAL HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 42 GLOBAL HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 GLOBAL RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 GLOBAL ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 GLOBAL DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 46 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 GLOBAL ADALIMUMAB MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 48 NORTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 49 NORTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 50 NORTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 51 NORTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 52 NORTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 53 NORTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 54 NORTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 55 NORTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 56 NORTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 57 NORTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 58 NORTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 59 U.S. ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 60 U.S. ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 61 U.S. BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 U.S. ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 63 U.S. ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 64 U.S. GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 65 U.S. ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 66 U.S. ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 67 U.S. ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 68 U.S. ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 69 CANADA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 70 CANADA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 CANADA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 CANADA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 73 CANADA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 74 CANADA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 75 CANADA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 76 CANADA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 77 CANADA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 78 CANADA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 79 MEXICO ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 80 MEXICO ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 81 MEXICO BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 82 MEXICO ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 83 MEXICO ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 84 MEXICO GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 85 MEXICO ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 86 MEXICO ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 87 MEXICO ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 88 MEXICO ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 89 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 90 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 91 EUROPE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 EUROPE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 94 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 95 EUROPE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 96 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 97 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 98 EUROPE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 99 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 100 GERMANYADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 101 GERMANYADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 102 GERMANYBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103 GERMANYADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 104 GERMANYADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 105 GERMANY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 106 GERMANYADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 107 GERMANYADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 108 GERMANYADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 109 GERMANYADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 110 U.K ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 111 U.K ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 112 U.K BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 113 U.K ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 114 U.K ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 115 U.K GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 116 U.K ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 117 U.K ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 118 U.K ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 119 U.K ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 120 ITALY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 121 ITALY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 122 ITALY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 123 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 124 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 125 ITALY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 126 ITALY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 127 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 128 ITALY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 129 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 130 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 131 FRANCE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132 FRANCE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 133 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 134 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 135 FRANCE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 136 FRANCE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 137 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 138 FRANCE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 139 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 140 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 141 SPAIN ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 142 SPAIN BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 144 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 145 SPAIN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 146 SPAIN ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 147 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 148 SPAIN ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 149 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 150 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 151 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 NETHERLANDS BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 154 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 155 NETHERLANDS GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 156 NETHERLANDS ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 157 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 158 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 159 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 160 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 161 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 162 RUSSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 163 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 164 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 165 RUSSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 166 RUSSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 167 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 168 RUSSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 171 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 SWITZERLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 174 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 175 SWITZERLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 176 SWITZERLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 177 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 178 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 179 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 180 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 181 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 BELGIUM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 183 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 184 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 185 BELGIUM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 186 BELGIUM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 187 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 188 BELGIUM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 189 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 190 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 191 TURKEY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192 TURKEY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 193 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 194 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 195 TURKEY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 196 TURKEY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 197 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 198 TURKEY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 199 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 200 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 201 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 202 AUSTRIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 203 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 204 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 205 AUSTRIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 206 AUSTRIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 207 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 208 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 209 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 210 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 211 NORWAY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 212 NORWAY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 213 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 214 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 215 NORWAY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 216 NORWAY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 217 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 218 NORWAY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 219 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 220 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 221 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 222 HUNGARY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 224 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 225 HUNGARY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 226 HUNGARY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 227 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 228 HUNGARY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 229 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 230 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 231 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 232 LITHUANIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 233 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 234 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 235 LITHUANIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 236 LITHUANIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 237 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 238 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 239 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 240 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 241 IRELAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 242 IRELAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 243 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 244 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 245 IRELAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 246 IRELAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 247 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 248 IRELAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 249 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 250 POLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 251 POLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 252 POLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 254 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 255 POLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 256 POLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 257 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 258 POLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 259 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 260 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 261 ASIA- PACIFIC ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 262 ASIA- PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 263 ASIA- PACIFIC ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 264 ASIA- PACIFIC BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 265 ASIA- PACIFIC ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 266 ASIA- PACIFIC ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 267 ASIA- PACIFIC GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 268 ASIA- PACIFIC ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 269 ASIA- PACIFIC ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 270 ASIA- PACIFIC ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 271 ASIA- PACIFIC ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 272 JAPANADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 273 JAPANADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 274 JAPANBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 275 JAPANADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 276 JAPANADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 277 JAPAN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 278 JAPANADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 279 JAPANADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 280 JAPANADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 281 JAPANADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 282 CHINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 283 CHINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 284 CHINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 285 CHINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 286 CHINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 287 CHINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 288 CHINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 289 CHINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 290 CHINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 291 CHINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 292 SOUTH KOREA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 293 SOUTH KOREA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 294 SOUTH KOREA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 295 SOUTH KOREA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 296 SOUTH KOREA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 297 SOUTH KOREA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 298 SOUTH KOREA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 299 SOUTH KOREA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 300 SOUTH KOREA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 301 SOUTH KOREA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 302 AUSTRALIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 303 AUSTRALIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 304 AUSTRALIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 305 AUSTRALIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 306 AUSTRALIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 307 AUSTRALIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 308 AUSTRALIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 309 AUSTRALIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 310 AUSTRALIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 311 AUSTRALIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 312 INDIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 313 INDIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 314 INDIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 315 INDIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 316 INDIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 317 INDIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 318 INDIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 319 INDIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 320 INDIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 321 INDIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 322 SINGAPORE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 323 SINGAPORE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 324 SINGAPORE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 325 SINGAPORE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 326 SINGAPORE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 327 SINGAPORE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 328 SINGAPORE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 329 SINGAPORE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 330 SINGAPORE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 331 SINGAPORE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 332 MALAYSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 333 MALAYSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 334 MALAYSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 MALAYSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 336 MALAYSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 337 MALAYSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 338 MALAYSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 339 MALAYSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 340 MALAYSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 341 MALAYSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 342 THAILAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 343 THAILAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 344 THAILAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 345 THAILAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 346 THAILAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 347 THAILAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 348 THAILAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 349 THAILAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 350 THAILAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 351 THAILAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 352 INDONESIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 353 INDONESIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 354 INDONESIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 355 INDONESIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 356 INDONESIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 357 INDONESIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 358 INDONESIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 359 INDONESIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 360 INDONESIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 361 INDONESIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 362 PHILIPPINES ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 363 PHILIPPINES ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 364 PHILIPPINES BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 PHILIPPINES ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 366 PHILIPPINES ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 367 PHILIPPINES GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 368 PHILIPPINES ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 369 PHILIPPINES ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 370 PHILIPPINES ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 371 PHILIPPINES ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 372 VIETNAM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 373 VIETNAM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 374 VIETNAM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 375 VIETNAM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 376 VIETNAM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 377 VIETNAM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 378 VIETNAM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 379 VIETNAM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 380 VIETNAM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 381 VIETNAM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 382 REST OF ASIA-PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 383 SOUTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 384 SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 385 SOUTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 386 SOUTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 387 SOUTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 388 SOUTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 389 SOUTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 390 SOUTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 391 SOUTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 392 SOUTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 393 SOUTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 394 BRAZILADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 395 BRAZILADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 396 BRAZILBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 397 BRAZILADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 398 BRAZILADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 399 BRAZIL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 400 BRAZILADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 401 BRAZILADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 402 BRAZILADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 403 BRAZILADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 404 ARGENTINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 405 ARGENTINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 406 ARGENTINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 407 ARGENTINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 408 ARGENTINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 409 ARGENTINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 410 ARGENTINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 411 ARGENTINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 412 ARGENTINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 413 ARGENTINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 414 PERU ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 415 PERU ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 416 PERU BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 417 PERU ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 418 PERU ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 419 PERU GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 420 PERU ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 421 PERU ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 422 PERU ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 423 PERU ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 424 REST OF SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 425 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 426 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 427 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 428 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 429 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 430 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 431 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 432 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 433 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 434 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 435 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 436 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 437 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 438 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 439 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 440 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 441 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 442 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 443 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 444 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 445 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 446 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 447 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 448 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 449 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 450 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 451 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 452 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 453 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 454 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 455 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 456 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 457 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 458 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 459 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 460 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 461 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 462 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 463 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 464 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 465 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 466 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 467 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 468 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 469 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 470 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 471 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 472 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 473 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 474 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 475 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 476 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 477 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 478 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 479 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 480 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 481 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 482 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 483 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 484 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 485 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 486 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 487 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 488 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 489 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 490 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 491 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 492 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 493 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 494 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 495 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 496 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 GLOBAL ADALIMUMAB MARKET: SEGMENTATION
FIGURE 2 GLOBAL ADALIMUMAB MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL ADALIMUMAB MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL ADALIMUMAB MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL ADALIMUMAB MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL ADALIMUMAB MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL ADALIMUMAB MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE HIGHEST GROWING REGION IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ADALIMUMAB MARKET IN 2020 & 2027
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ADALIMUMAB MARKET
FIGURE 16 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 17 FUNCTION OF CRO
FIGURE 18 HEALTHCARE EXPENDITURE IN 2016 AND 2019
FIGURE 19 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019
FIGURE 20 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)
FIGURE 21 GLOBAL ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)
FIGURE 22 GLOBAL ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 23 GLOBAL ADALIMUMAB MARKET: BY TYPE, 2019
FIGURE 24 GLOBAL ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)
FIGURE 25 GLOBAL ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 26 GLOBAL ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019
FIGURE 28 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION)
FIGURE 29 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027)
FIGURE 30 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE
FIGURE 31 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, 2019
FIGURE 32 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION)
FIGURE 33 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 34 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 35 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 36 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 37 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 38 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019
FIGURE 40 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION)
FIGURE 41 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027)
FIGURE 42 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019
FIGURE 44 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 45 GLOBAL ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027)
FIGURE 46 GLOBAL ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 48 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 49 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 50 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 GLOBAL ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 52 GLOBAL ADALIMUMAB MARKET: BY REGION (2019)
FIGURE 53 GLOBAL ADALIMUMAB MARKET: BY REGION (2020 & 2027)
FIGURE 54 GLOBAL ADALIMUMAB MARKET: BY REGION (2019 & 2027)
FIGURE 55 GLOBAL ADALIMUMAB MARKET: BY INDICATION (2020-2027)
FIGURE 56 NORTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 57 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 58 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 59 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 60 NORTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 61 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 62 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 63 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 64 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 65 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 66 ASIA- PACIFIC ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 67 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 68 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 ASIA- PACIFIC ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 71 SOUTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 72 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 73 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 SOUTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 76 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 77 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 78 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 79 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 80 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 81 GLOBAL ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 82 NORTH AMERICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 83 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
FIGURE 84 ASIA-PACIFIC ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
